| Trial ID: | L0904 |
| Source ID: | NCT01502267
|
| Associated Drug: |
High Dose Ivig And B Cell Depleting Agents
|
| Title: |
Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: High dose IVIG and B cell depleting agents
|
| Outcome Measures: |
Primary: The rates of kidney transplantation, from one to five years | Secondary: Reduction in anti-HLA alloantibodies, 1year|Renal allograft survival, graft and patient survival, from one to five year|The number of serious complication, from one to five year
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Hospital | Collaborators: Roche Pharma AG
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-01
|
| Completion Date: |
2016-01
|
| Results First Posted: |
|
| Last Update Posted: |
2012-01-06
|
| Locations: |
Seoul National University Hospital, Seoul, 110-799, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01502267
|
